Craig-Hallum initiated coverage of iSpecimen with a rating of Buy and set a new price target of $20.00

EF Hutton reiterated coverage of iSpecimen with a rating of Buy and set a new price target of $12.00 from $10.00 previously

Woburn, Massachusetts--(Newsfile Corp. - August 21, 2025) - iSpecimen Inc. (NASDAQ:ISPC), an online marketplace for human biospecimens, today announced the successful completion of Milestone 1 in its digital transformation program powered by Salestack Solutions. This critical achievement marks the installation of the Salestack platform and provisioning of modern infrastructure—laying the foundation for accelerated innovation, operational efficiency, and long-term scalability.Milestone 1 focused on enhancing the legacy iSpecimen Marketplace® infrastructure with Salestack's next-generation, cloud-native architecture, expected to deliver immediate value through:Infrastructure-as-Code (IaC): bui

Woburn, Massachusetts--(Newsfile Corp. - August 7, 2025) - iSpecimen Inc. (NASDAQ:ISPC), a technology-enabled company modernizing the way human biospecimens are sourced for scientific research, today announced a major strategic initiative aimed at integrating digital assets into its business model. The company is looking to build an up to $200 million corporate treasury reserve based on the Solana blockchain ecosystem.iSpecimen has retained WestPark Capital to advise on the initiative with any funds that may be allocated or raised to be earmarked for building a digital asset treasury that will support long-term value creation and fuel innovation across iSpecimen's digital infrastructure. To

WOBURN, Mass., Aug. 04, 2025 (GLOBE NEWSWIRE) -- iSpecimen Inc. (NASDAQ:ISPC) ("iSpecimen" or the "Company"), an online global marketplace that connects scientists requiring biospecimens for medical research with a network of healthcare specimen providers, today announced that it closed its previously announced private placement pursuant to a securities purchase agreement with accredited investors for aggregate gross proceeds of approximately $1.75 million, before deducting fees to the placement agent and other offering expenses payable by the Company. The Company intends to use the net proceeds from the offering to pay $500,000 for marketing and advertising services to be provided by IR

WOBURN, Mass., July 31, 2025 (GLOBE NEWSWIRE) -- iSpecimen Inc. (NASDAQ:ISPC) ("iSpecimen" or the "Company"), an online global marketplace that connects scientists requiring biospecimens for medical research with a network of healthcare specimen providers, today announced that it entered into a securities purchase agreement with accredited investors for aggregate gross proceeds of approximately $1.75 million, before deducting fees to the placement agent and other offering expenses payable by the Company. The Company intends to use the net proceeds from the offering to pay $500,000 for marketing and advertising services to be provided by IR Agency LLC, and the remainder for working capital

WOBURN, Mass., July 28, 2025 (GLOBE NEWSWIRE) -- This press release corrects a version issued on July 25, 2025 that incorrectly listed KCSA Strategic Communications as iSpecimen's investor relations contact. KCSA is not currently affiliated with iSpecimen Inc. and was mistakenly included in the prior release. The corrected release is below in its entirety. iSpecimen Inc. (NASDAQ:ISPC) ("iSpecimen" or the "Company"), an online global marketplace that connects scientists requiring biospecimens for medical research with a network of healthcare specimen providers, announced on July 25, 2025 the closing of its previously announced underwritten public offering of 5,714,283 shares of its common

WOBURN, Mass., July 28, 2025 (GLOBE NEWSWIRE) -- This press release corrects the version issued on July 24, 2025 that incorrectly listed KCSA Strategic Communications as iSpecimen's investor relations contact. KCSA is not currently affiliated with iSpecimen Inc. and was mistakenly included in the prior release. The corrected release is below in its entirety. iSpecimen Inc. (NASDAQ:ISPC) ("iSpecimen" or the "Company"), an online global marketplace that connects scientists requiring biospecimens for medical research with a network of healthcare specimen providers, announced on July 24, 2025  the pricing of an underwritten public offering of 5,714,283 shares of its common stock (or pre-fund

WOBURN, Mass., July 25, 2025 (GLOBE NEWSWIRE) -- iSpecimen Inc. (NASDAQ:ISPC) ("iSpecimen" or the "Company"), an online global marketplace that connects scientists requiring biospecimens for medical research with a network of healthcare specimen providers, announced today the closing of its previously announced underwritten public offering of 5,714,283 shares of its common stock (or pre-funded warrants to purchase common stock in lieu thereof) at a public offering price of $0.70 per share (the "Offering"). The aggregate gross proceeds to the Company from the Offering was approximately $4 million, before deducting underwriting discounts and commissions and other offering expenses. The Comp

WOBURN, Mass., July 24, 2025 (GLOBE NEWSWIRE) -- iSpecimen Inc. (NASDAQ:ISPC) ("iSpecimen" or the "Company"), an online global marketplace that connects scientists requiring biospecimens for medical research with a network of healthcare specimen providers, announced today the pricing of an underwritten public offering of 5,714,283 shares of its common stock (or pre-funded warrants to purchase common stock in lieu thereof) at a public offering price of $0.70 per share (the "Offering"). The aggregate gross proceeds to the Company from the Offering are expected to be approximately $4 million, before deducting underwriting discounts and commissions and other estimated offering expenses. The O

WOBURN, Mass., Nov. 07, 2024 (GLOBE NEWSWIRE) -- iSpecimen Inc. (NASDAQ:ISPC) ("iSpecimen" or the "Company"), an online global marketplace that connects scientists requiring biospecimens for medical research with a network of healthcare specimen providers, announced today a significant enhancement to its searchable inventory that provides researchers with increased access to a wide array of biospecimens vital to advancing oncology research and treatments. The expanded inventory includes highly sought-after cancer samples across a variety of tumor types, stages, and patient demographics, enabling researchers to access the specific samples they need efficiently and by cancer type, includi

LEXINGTON, Mass., Nov. 07, 2024 (GLOBE NEWSWIRE) -- iSpecimen Inc. (NASDAQ:ISPC) ("iSpecimen" or the "Company"), an online global marketplace that connects scientists requiring biospecimens for medical research with a network of healthcare specimen providers, today reported its financial and operating results for the three and nine month periods ended September 30, 2024. "The third quarter was a period of continued strategic transformation for iSpecimen, primarily driven by several key initiatives," said Tracy Curley, CEO of iSpecimen. "First, we completed a 1-for-20 reverse stock split which helped the Company maintain its Nasdaq listing. Additionally, we secured a $1,000,000 loan facili

3 - iSpecimen Inc. (0001558569) (Issuer)

3 - iSpecimen Inc. (0001558569) (Issuer)

3 - iSpecimen Inc. (0001558569) (Issuer)

4 - iSpecimen Inc. (0001558569) (Issuer)

4 - iSpecimen Inc. (0001558569) (Issuer)

4 - iSpecimen Inc. (0001558569) (Issuer)

3 - iSpecimen Inc. (0001558569) (Issuer)

3 - iSpecimen Inc. (0001558569) (Issuer)

4 - iSpecimen Inc. (0001558569) (Issuer)

4 - iSpecimen Inc. (0001558569) (Issuer)

LEXINGTON, Mass., Jan. 24, 2023 (GLOBE NEWSWIRE) -- iSpecimen Inc. (NASDAQ:ISPC) ("iSpecimen" or the "Company"), an online global marketplace that connects scientists in need of biospecimens for medical research with a network of healthcare specimen providers, announced today that it appointed Eric Langlois as Chief Revenue Officer, effective immediately. Mr. Langlois previously served as the Company's Senior Vice President of Sales and Business Development. In this new role, Mr. Langlois will manage a restructured commercial team aimed at executing on Company initiatives to better align customer needs, streamline collaboration, support innovation and productivity necessary for driving sca

LEXINGTON, Mass., Jan. 10, 2023 (GLOBE NEWSWIRE) -- iSpecimen Inc. (NASDAQ:ISPC) ("iSpecimen" or the "Company"), an online global marketplace that connects scientists in need of biospecimens for medical research with a network of healthcare specimen providers, announced today that its Board of Directors has appointed Tracy Curley, former Interim CEO, as CEO, effective immediately. "I am grateful to the Board and the entire team at iSpecimen for their support over the past four months, and for the confidence they have shown in my ability to lead the Company," said Tracy Curley, CEO of iSpecimen. "The progress we've made this year in terms of operational and financial execution is encouragi

LEXINGTON, Mass., Dec. 05, 2022 (GLOBE NEWSWIRE) -- iSpecimen Inc. (NASDAQ:ISPC) ("iSpecimen" or the "Company"), an online global marketplace that connects scientists in need of biospecimens for medical research with a network of healthcare specimen providers, announced today that the Company has appointed Joseph J. Basile to iSpecimen's Board of Directors (the "Board"), as well as the audit committee and the nominating and corporate governance committee of the Company, effective November 28, 2022. Mr. Basile is replacing Margaret H. Lawrence as an independent director. Mr. Basile is a sought-after strategic advisor, an accomplished business leader, a skilled negotiator, a trained mediato

LEXINGTON, Mass., Sept. 22, 2022 (GLOBE NEWSWIRE) -- iSpecimen Inc. (NASDAQ:ISPC) ("iSpecimen" or the "Company"), an online global marketplace that connects scientists in need of biospecimens for medical research with a network of healthcare specimen providers, announced today the immediate appointment of Tracy Curley as interim CEO, replacing current Chief Executive Officer and President, Christopher Ianelli. In addition to serving as interim CEO, Ms. Curley will remain CFO. The Board of Directors (the "Board") is currently reviewing the Company's near- and long-term needs pertaining to the role of Chief Executive Officer. On September 19, 2022, Dr. Ianelli gave the Board a notice of dep

LEXINGTON, Mass., June 08, 2022 (GLOBE NEWSWIRE) -- iSpecimen Inc. (NASDAQ:ISPC) ("iSpecimen" or the "Company"), an online global marketplace that connects scientists in need of biospecimens for medical research with a network of healthcare specimen providers, announced today that the Company has appointed Evan Cox as Vice President of Product Management, effective immediately. In this role, Mr. Cox will manage the growth and future development of the iSpecimen Marketplace™ platform. "Evan's previous experience in planning, developing and delivering technology solutions for leading healthcare organizations will prove vital as we continue to enhance and expand our Marketplace offering," sa

LEXINGTON, Mass., Oct. 26, 2021 /PRNewswire/ -- iSpecimen Inc. (NASDAQ:ISPC) ("iSpecimen" or the "Company"), an online marketplace for human biospecimens, today announced that it has appointed Erik Uribe as Director of Global Implementations. Mr. Uribe will be responsible for advancing the development of the iSpecimen Marketplace™ and tightening its integration with customer and supplier workflows and systems to ensure a continuously streamlined experience. Mr. Uribe joins iSpecimen's ongoing program to help expand the iSpecimen Marketplace platform's capabilities, enabling cu

Revenue increased 76% year-over-year to approximately $2.86 million Brielan Smiechowski Named SVP of Sales and Business Development LEXINGTON, Mass., Aug. 06, 2024 (GLOBE NEWSWIRE) -- iSpecimen Inc. (NASDAQ:ISPC) ("iSpecimen" or the "Company"), an online global marketplace that connects scientists requiring biospecimens for medical research with a network of healthcare specimen providers, today reported its financial and operating results for the three and six month periods ended June 30, 2024. "iSpecimen's strong results reflect the progress we have made towards operational improvements throughout the Company this year, resulting in a 76% increase in revenue to $2.86 million for

LEXINGTON, Mass., July 25, 2024 (GLOBE NEWSWIRE) -- iSpecimen Inc. (NASDAQ:ISPC) ("iSpecimen" or the "Company"), an online global marketplace that connects scientists requiring biospecimens for medical research with a network of healthcare specimen providers, today announced that it will report its financial results for the second quarter ended June 30, 2024, before the market opens on Tuesday, August 6, 2024. The Company will host a conference call and audio webcast that morning at 8:30 a.m. Eastern Time featuring remarks by Tracy Curley, CEO. Event:iSpecimen Second Quarter 2024 Results Conference Call  Date:Tuesday, August 6, 2024  Time:8:30 a.m. Eastern Time  Live Call:+1-800-717-1738

LEXINGTON, Mass., May 07, 2024 (GLOBE NEWSWIRE) -- iSpecimen Inc. (NASDAQ:ISPC) ("iSpecimen" or the "Company"), an online global marketplace that connects scientists requiring biospecimens for medical research with a network of healthcare specimen providers, today reported its financial and operating results for the three-month period ended March 31, 2024. "iSpecimen made tremendous progress during the first quarter advancing our most promising operational initiative, Next Day Quotes, a program that expedites the biospecimen transaction process, which has helped elevate our market position and is expected to contribute meaningfully to our growth in 2024 and beyond," said Tracy Curley, C

LEXINGTON, Mass., April 25, 2024 (GLOBE NEWSWIRE) -- iSpecimen Inc. (NASDAQ:ISPC) ("iSpecimen" or the "Company"), an online global marketplace that connects scientists requiring biospecimens for medical research with a network of healthcare specimen providers, today announced that it will report its financial results for the first quarter of 2024 ended March 31, 2024 before the market opens on Tuesday, May 7, 2024. The Company will host a conference call and audio webcast that morning at 8:30 a.m. Eastern Time featuring remarks by Tracy Curley, CEO. Event: iSpecimen First Quarter 2024 Results Conference CallDate: Tuesday, May 7, 2024Time: 8:30 a.m. Eastern TimeDial in: 1-800-717-1738 (U.S

LEXINGTON, Mass., March 14, 2024 (GLOBE NEWSWIRE) -- iSpecimen Inc. (NASDAQ:ISPC) ("iSpecimen" or the "Company"), an online global marketplace that connects scientists requiring biospecimens for medical research with a network of healthcare specimen providers, today reported its financial and operating results for the twelve-month period ended December 31, 2023. "Throughout 2023, we advanced our objective to reach profitability, focusing on right-sizing our business and implementing new operational efficiencies," said Tracy Curley, CEO of iSpecimen. "As we strive to become cash flow positive, we are focusing our efforts on growing topline revenues through our core business segments by cap

LEXINGTON, Mass., March 12, 2024 (GLOBE NEWSWIRE) -- iSpecimen Inc. (NASDAQ:ISPC) ("iSpecimen" or the "Company"), an online global marketplace that connects scientists requiring biospecimens for medical research with a network of healthcare specimen providers, today announced that it will report its financial results for the full year ended December 31, 2023 after the market closes on Wednesday, March 13, 2024. The Company had previously announced it would report its financial results before the market opens on March 13, 2024, with the conference call taking place at 8:30 a.m. Eastern Time on March 13, 2024. The Company will now host a conference call and audio webcast on Thursday, Ma

LEXINGTON, Mass., March 05, 2024 (GLOBE NEWSWIRE) -- iSpecimen Inc. (NASDAQ:ISPC) ("iSpecimen" or the "Company"), an online global marketplace that connects scientists requiring biospecimens for medical research with a network of healthcare specimen providers, today announced that it will report its financial results for the full year ended December 31, 2023 before the market opens on Wednesday, March 13, 2024. The Company will host a conference call and audio webcast that morning at 8:30 a.m. Eastern Time featuring remarks by Tracy Curley, CEO. Event:iSpecimen Year End 2023 Results Conference CallDate:Wednesday, March 13, 2024Time:8:30 a.m. Eastern TimeDial in:1-888-886-7786 (U.S. Toll F

LEXINGTON, Mass., Nov. 02, 2023 (GLOBE NEWSWIRE) -- iSpecimen Inc. (NASDAQ:ISPC) ("iSpecimen" or the "Company"), an online global marketplace that connects scientists requiring biospecimens for medical research with a network of healthcare specimen providers, today reported its financial and operating results for the three and nine month periods ended September 30, 2023. Q3 2023 Financial Results & Recent Operational Highlights Revenue of $2.8 million for the three-month period ended September 30, 2023, compared to $2.6 million for the same period in 2022. Revenue increased $1.2 million, or 75% sequentially, from $1.6 million in Q2 2023;For the third q

LEXINGTON, Mass., Oct. 23, 2023 (GLOBE NEWSWIRE) -- iSpecimen Inc. (NASDAQ:ISPC) ("iSpecimen" or the "Company"), an online global marketplace that connects scientists requiring biospecimens for medical research with a network of healthcare specimen providers, announced today preliminary financial results for the third quarter of 2023. The Company expects third quarter 2023 revenue to be between $2.6 to $2.8 million, representing an increase of between 60% to 70% from second quarter 2023 revenue of $1.63 million. The launch of the iSpecimen's next-day quote program in the third quarter of 2023 is a key driver of the Company's higher financial performance for the third quarter of 2023, as i

LEXINGTON, Mass., Aug. 02, 2023 (GLOBE NEWSWIRE) -- iSpecimen Inc. (NASDAQ:ISPC) ("iSpecimen" or the "Company"), an online global marketplace that connects scientists requiring biospecimens for medical research with a network of healthcare specimen providers, today reported its financial and operating results for the three and six month periods ended June 30, 2023. "In the second quarter we focused our efforts on advancing key revenue enhancement opportunities that are complementary to our core business, including sequencing, embedded coordinators and a reboot of our remnant line of business, as well as integrating new technologies to the iSpecimen Marketplace to enhance our

SC 13G/A - iSpecimen Inc. (0001558569) (Subject)

SC 13D - iSpecimen Inc. (0001558569) (Subject)

SC 13G/A - iSpecimen Inc. (0001558569) (Subject)

SC 13G/A - iSpecimen Inc. (0001558569) (Subject)

SC 13G/A - iSpecimen Inc. (0001558569) (Subject)

SC 13G - iSpecimen Inc. (0001558569) (Subject)

SC 13G - iSpecimen Inc. (0001558569) (Subject)

SC 13G - iSpecimen Inc. (0001558569) (Subject)

SC 13G - iSpecimen Inc. (0001558569) (Subject)